Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study.

导出 LinkOut

翻译打印收藏纠错

作者： Yu-Qing,Zhang ^[1] ; Kang,Wang ^[2] ; Jin-Kai,Feng ^[2] ; Lu-Yun,Yuan ^[2] ; Chao,Liang ^[1] ; Yan-Jun,Xiang ^[2] ; Xu,Wang ^[3] ; Fei-Fei,Mao ^[2] ; Shu-Qun,Cheng ^[1]

作者单位： Cancer Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. ^[1] Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. ^[2] Department of Hepatobiliary Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. ^[3] Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. ^[4]

关键词 camrelizumab combination (combined) therapy gemcitabine and oxaliplatin (GEMOX)immune checkpoint inhibitor (ICI)intrahepatic cholangiocarcinoma (ICC)prognosis tumor response

DOI 10.3389/fonc.2023.1101038

PMID 37197414

发布时间 2023-05-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2023年13卷

1101038页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除